Lymphoma, Large B-Cell, Diffuse Clinical Trials

112 clinical trials for Lymphoma, Large B-Cell, Diffuse across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) — RECRUITING · PHASE1
• A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) — RECRUITING · PHASE2
• A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) — RECRUITING · PHASE1
• A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies — RECRUITING · PHASE1
• CD70-targeted immunoPET Imaging of Malignant Cancers — RECRUITING · PHASE2
• A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma — RECRUITING · PHASE2
• A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies — RECRUITING · PHASE1
• EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection — COMPLETED · PHASE2
• A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers — TERMINATED · PHASE1
• A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers — TERMINATED · PHASE1
• Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies — NOT_YET_RECRUITING · NA
• Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab — COMPLETED · PHASE3
• A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) — COMPLETED · PHASE2
• Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell — COMPLETED
• Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol — OTHER
• LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) — ACTIVE_NOT_RECRUITING · PHASE1
• A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) — COMPLETED · PHASE2
• Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study — TERMINATED
• A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) — COMPLETED · PHASE2
• Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL — ACTIVE_NOT_RECRUITING · PHASE2
• An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma — TERMINATED · PHASE2
• Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma — WITHDRAWN · PHASE1
• Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah — WITHDRAWN · PHASE1
• A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) — ACTIVE_NOT_RECRUITING · PHASE2
• Fatigue Reduction Diet in Lymphoma Survivors — COMPLETED · NA
• A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL — NOT_YET_RECRUITING · PHASE3
• A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) — TERMINATED · PHASE1
• Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis — OTHER · PHASE2
• A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies — COMPLETED · PHASE1
• Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL — NOT_YET_RECRUITING · NA
• Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma — TERMINATED · PHASE1
• Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) — COMPLETED · PHASE2
• Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma — COMPLETED · PHASE1
• A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. — COMPLETED · PHASE1
• A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL) — COMPLETED · PHASE2
• Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL — COMPLETED · PHASE2
• Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma — OTHER
• Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma — COMPLETED · PHASE3
• A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors — TERMINATED · PHASE1
• A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma — COMPLETED · PHASE2
• Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel — TERMINATED · NA
• Safety Study of SEA-CD40 in Cancer Patients — TERMINATED · PHASE1
• CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma — OTHER · PHASE1
• Tumor Heterogeneity in Diffuse Large B-cell Lymphoma in Relation to CNS Involvement and Cell-free DNA — COMPLETED
• Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines — OTHER · PHASE3
• A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma — COMPLETED

Refine this search